Estimating Longitudinal Risks and Benefits From Cardiovascular Preventive Therapies Among Medicare Patients

被引:11
|
作者
Lloyd-Jones, Donald M.
Huffman, Mark D.
Karmali, Kunal N.
Sanghavi, Darshak M.
Wright, Janet S.
Pelser, Colleen
Gulati, Martha
Masoudi, Frederick A.
Goff, David C., Jr.
机构
关键词
AHA Scientific Statements; cardiovascular diseases; morbidity; mortality; myocardial infarction; population; prevention; stroke; ASSOCIATION TASK-FORCE; ADULT TREATMENT PANEL; OUTCOME INCIDENCE; NATIONAL-HEALTH; MULTIFACTORIAL INTERVENTION; MYOCARDIAL-INFARCTION; STATIN ELIGIBILITY; LOWERING TREATMENT; AMERICAN-COLLEGE; UNITED-STATES;
D O I
10.1016/j.jacc.2016.10.018
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The Million Hearts Initiative has a goal of preventing 1 million heart attacks and strokes-the leading causes of mortality-through several public health and healthcare strategies by 2017. The American Heart Association and American College of Cardiology support the program. The Cardiovascular Risk Reduction Model was developed by Million Hearts and the Center for Medicare & Medicaid Services as a strategy to assess a value-based payment approach toward reduction in 10-year predicted risk of atherosclerotic cardiovascular disease (ASCVD) by implementing cardiovascular preventive strategies to manage the "ABCS" (aspirin therapy in appropriate patients, blood pressure control, cholesterol management, and smoking cessation). The purpose of this special report is to describe the development and intended use of the Million Hearts Longitudinal ASCVD Risk Assessment Tool. The Million Hearts Tool reinforces and builds on the "2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk"by allowing clinicians to estimate baseline and updated 10-year ASCVD risk estimates for primary prevention patients adhering to the appropriate ABCS over time, alone or in combination. The tool provides updated risk estimates based on evidence from high-quality systematic reviews and meta-analyses of the ABCS therapies. This novel approach to personalized estimation of benefits from risk-reducing therapies in primary prevention may help target therapies to those in whom they will provide the greatest benefit, and serves as the basis for a Center for Medicare & Medicaid Services program designed to evaluate the Million Hearts Cardiovascular Risk Reduction Model.
引用
收藏
页码:1617 / 1636
页数:20
相关论文
共 50 条
  • [1] Estimating Longitudinal Risks and Benefits From Cardiovascular Preventive Therapies Among Medicare Patients The Million Hearts Longitudinal ASCVD Risk Assessment Tool: A Special Report From the American Heart Association and American College of Cardiology
    Lloyd-Jones, Donald M.
    Huffman, Mark D.
    Karmali, Kunal N.
    Sanghavi, Darshak M.
    Wright, Janet S.
    Pelser, Colleen
    Gulati, Martha
    Masoudi, Frederick A.
    Goff, David C., Jr.
    CIRCULATION, 2017, 135 (13) : E793 - +
  • [2] Estimating Longitudinal Risks and Benefits From Cardiovascular Preventive Therapies Among Medicare Patients: The Million Hearts Longitudinal ASCVD Risk Assessment Tool: A Special Report From the American Heart Association and American College of Cardiology (vol 69, pg 1617, 2017)
    Lloyd-Jones, D. M.
    Huffman, M. D.
    Karmali, K. N.
    Sanghavi, D. M.
    Wright, J. S.
    Pelser, C.
    Gulati, M.
    Masoudi, F. A.
    Goff, D. C., Jr.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (12) : 1651 - 1651
  • [4] Bariatric surgery in Medicare patients: greater risks but substantial benefits
    Yuan, Xiang
    Hawver, Lisa. R. Martin
    OJo, Peter
    Wolfe, Luke A.
    Meador, Jill G.
    Kellum, John M.
    Maher, James W.
    SURGERY FOR OBESITY AND RELATED DISEASES, 2009, 5 (03) : 299 - 304
  • [5] ESTIMATING LIFETIME BENEFITS OF OPTIMIZING SECONDARY PREVENTIVE TREATMENT FOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
    Gill, J. L.
    Miracolo, A.
    Politopoulou, K.
    Jayawardana, S.
    Apostolou, E. A.
    Carter, A. W.
    Kanavos, P.
    VALUE IN HEALTH, 2023, 26 (12) : S393 - S393
  • [6] Unrecognized Cardiovascular Emergencies Among Medicare Patients
    Waxman, Daniel A.
    Kanzaria, Hemal K.
    Schriger, David L.
    JAMA INTERNAL MEDICINE, 2018, 178 (04) : 477 - 484
  • [7] CARDIOVASCULAR EFFECTS OF ANTIANGIOGENIC ONCOLOGICAL THERAPIES. THE FINE BALANCE OF BENEFITS AND RISKS
    Jurcut, Ruxandra
    Popara-Voica, Anca Maria
    Serbanescu, Georgia-Luiza
    Croitoru, Adina
    Ginghina, Octav
    Ionita, Oana
    Anghel, Rodica
    Ginghina, Carmen
    FARMACIA, 2016, 64 (01) : 13 - 23
  • [8] Sham trials: benefits and risks for cardiovascular research and patients
    Fudim, Marat
    Ali-Ahmed, Fatima
    Patel, Manesh R.
    Sobotka, Paul A.
    LANCET, 2019, 393 (10186): : 2104 - 2106
  • [9] Coordinated Care for Optimization of Cardiovascular Preventive Therapies in Patients With Diabetes
    Hsu, Nin-Chieh
    Fu, Yin-Chih
    Hsu, Chia-Hao
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 330 (08): : 771 - 771
  • [10] Balancing Benefits and Risks in Patients Receiving Incretin-Based Therapies: Focus on Cardiovascular and Pancreatic Side Effects
    Haluzik, Martin
    Mraz, Milos
    Svacina, Stepan
    DRUG SAFETY, 2014, 37 (12) : 1003 - 1010